Turn Therapeutics (NASDAQ:TTRX) Cut to “Sell” at Wall Street Zen

Wall Street Zen cut shares of Turn Therapeutics (NASDAQ:TTRX) from a hold rating to a sell rating in a research report report published on Saturday,Wall Street Zen reports.

A number of other brokerages have also recently issued reports on TTRX. Weiss Ratings cut shares of Turn Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 18th. WBB Securities reaffirmed a “sell” rating and issued a $10.00 price objective on shares of Turn Therapeutics in a research note on Monday, September 14th. Zacks Research upgraded Turn Therapeutics to a “hold” rating in a research report on Tuesday, July 21st. Lucid Cap Mkts raised Turn Therapeutics to a “strong-buy” rating in a report on Thursday, September 24th. Finally, LADENBURG THALM/SH SH upgraded Turn Therapeutics to a “strong-buy” rating in a research report on Monday, July 20th. Two investment analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $9.00.

Turn Therapeutics Stock Performance

NASDAQ:TTRX opened at $13.04 on Friday. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 8.83. Turn Therapeutics has a fifty-two week low of $2.57 and a fifty-two week high of $26.50. The stock has a market cap of $388.46 million and a PE ratio of -44.97. The firm’s fifty day simple moving average is $10.72 and its 200-day simple moving average is $7.08.

Turn Therapeutics (NASDAQ:TTRX) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.20) EPS for the quarter. Analysts expect that Turn Therapeutics will post -0.4 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Turn Therapeutics

Institutional investors have recently made changes to their positions in the stock. Tamar Securities LLC acquired a new stake in shares of Turn Therapeutics during the fourth quarter valued at $59,000. Bank of America Corp DE acquired a new position in Turn Therapeutics in the 2nd quarter valued at about $103,000. Jefferies Financial Group Inc. acquired a new position in Turn Therapeutics in the 2nd quarter valued at about $119,000. DDFG Inc lifted its holdings in Turn Therapeutics by 34.9% in the 1st quarter. DDFG Inc now owns 70,534 shares of the company’s stock valued at $226,000 after purchasing an additional 18,246 shares in the last quarter. Finally, Bridgewater Advisors Inc. acquired a new stake in shares of Turn Therapeutics during the 2nd quarter worth about $242,000.

About Turn Therapeutics

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.